Cardlytics Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results and Issued Q2 Revenue Guidance With Its Midpoint Below Estimates. Also, Needham Maintained a Buy Rating on the Stock and Lowered Its Price Target From $17 to $12.
Cardlytics Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results and Issued Q2 Revenue Guidance With Its Midpoint Below Estimates. Also, Needham Maintained a Buy Rating on the Stock and Lowered Its Price Target From $17 to $12.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.